Scientific experts finalised to serve on EMA's pharmacovigilance panel
This article was originally published in SRA
The European Commission has appointed six independent scientific experts to serve on the European Medicines Agency's newly-constituted Pharmacovigilance Risk Assessment Committee that will hold its first meeting in July. It has also placed a further five experts on the reserve list1.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.